Imaging: reports and image quality

Software that drafts radiology report impressions, removes noise from MRI scans so protocols can run faster, or outlines and scores suspicious lesions on prostate MRI for the radiologist.

4 tools · Reviewed · How we grade

Two side by side monitors, one showing a report with an amber check mark, the other an image split into noisy and clean halves.
Category overviewHide category overview

Deep learning tools that clean up MRI images were cleared through 510(k): SubtleMR as radiological image processing software and AIR Recon DL as a reconstruction feature of GE's MRI systems, on image quality tests and reader studies of image appearance. Published studies are mostly small reader studies in which radiologists rated faster, processed scans as equal or better, such as a 61-patient spine study with 40% shorter scans. Independent work has found limits: one study found brain lesions under 4 mm missed on half-time processed scans, and another found that reconstruction shifted brain volume measurements. No study found here measured scanner throughput, repeat scans or patient outcomes.

No FDA clearance was found for the impression drafting tool reviewed here; the one vendor study found, a retrospective rating of 200 CT reports, did not measure reporting time or editing. Prostate MRI detection software is cleared on reader studies such as the 247-case study behind DeepHealth ProstateAI.

Read as an explainer

Grade CAccuracy studies only

AIR Recon DL

GE HealthCare

GE HealthCare's deep learning MRI reconstruction that removes noise and ringing artifacts from images.

FDA: 510(k) clearance

Full reviewHide full review: AIR Recon DL

AIR Recon DL is a deep learning reconstruction feature on GE HealthCare 1.5T, 3.0T and 7.0T MRI scanners that reduces noise and ringing (truncation artifacts) in images of all anatomies and patients of all ages, its 2025 clearance states; FDA's summary says it can be used to reduce scan time and is activated with a purchased software option key.

Why this grade. Studies measured image quality and diagnostic accuracy, including an arthroscopy-validated study of 117 patients scanned with a 7-minute knee protocol and the reader study behind the 2022 clearance (133 cases, three radiologists); none measured an effect on patient care or scanner throughput, which a B would require.

The evidence

In the 2022 clearance's reader study, three radiologists compared images reconstructed with and without the feature from the same data in 133 cases; processed images were equivalent or better for apparent signal-to-noise ratio and sharpness in all cases and preferred in 99% of evaluations. At New York University, 117 patients who had a 7-minute knee MRI with the feature and then arthroscopy were read by seven radiologists: sensitivity and specificity were 97% and 98% for anterior cruciate ligament tears and 89% and 87% for medial meniscus tears. In 50 volunteers in Rome, liver diffusion imaging took 207.3 seconds with the feature versus 513.6 seconds with a conventional high-resolution protocol.

In 74 healthy adults in Beijing, the feature improved image quality but shifted brain morphometry, raising hippocampal volumes by about 3.9%. A Nottingham comparison found other denoising methods gave better diffusion fiber orientation estimates.

FDA
AIR Recon DL was cleared for GE 3.0T systems as part of the SIGNA Premier (K193282, April 10, 2020), the predicate named in a later summary. FDA cleared it for all anatomies and ages through K213717 on June 8, 2022, and an updated version through K252379 on Dec. 23, 2025.
Randomized trial
None published
Key study
AJR, 2026, arthroscopy-validated accuracy study of a 7-minute knee MRI protocol at New York University, 117 patients
Limits
Studies are mostly single-center reader studies of image appearance or accuracy, and the clearance reader study was the company's; none compared patient outcomes or workflow with and without the feature, and quantitative brain measurements changed with it.
Cost
No published price found. checked
Specialties
Radiology
Checked against its sources
Grade CAccuracy studies only

DeepHealth ProstateAI

Quantib B.V. (RadNet) · Quantib Prostate

Prostate MRI software that segments the gland and flags suspected cancer lesions for radiologists to review.

FDA: 510(k) clearance

Full reviewHide full review: DeepHealth ProstateAI

The current version analyzes T2-weighted and diffusion MRI of men 40 and older and outputs candidate regions, each outlined and classed as low, moderate or high suspicion, as a concurrent reading aid, its 2026 clearance says. The earlier Quantib Prostate segmented the gland, computed volumes and offered a structured PI-RADS scoring workflow, per its 2020 clearance.

Why this grade. The evidence is reader studies, including a 110-patient study with a biopsy reference in which Quantib Prostate improved only an inexperienced reader's performance, and the company's FDA reader study; none measured an effect on biopsy decisions or patient outcomes, which a B would require.

The evidence

At San Raffaele in Milan, three readers of differing experience read multiparametric MRI of 110 men, 102 of whom had biopsy; clinically significant cancer was found in 47%. With the software, the least experienced reader identified 127 lesions rather than 101 and that reader's negative predictive value rose from 0.65 to 0.82; the two more experienced readers did not change. At Sapienza University in Rome, four novice readers of 200 scans agreed with an expert more with the software for two readers and less for two (one fell from a kappa of 0.603 to 0.292). In 170 retrospective scans at the same center, the software did not significantly change diagnostic performance but shortened reporting time, from 8.23 to 7.11 minutes for an inexperienced reader.

The 2026 FDA summary reports a standalone case-level area under the curve of 0.819; 86% of high-suspicion lesions in its validation set were cancer. None of the three Italian studies listed company authors.

FDA
FDA cleared Quantib Prostate through 510(k) K202501 on Oct. 11, 2020, as image processing software, and DeepHealth ProstateAI, a computer-aided detection and diagnosis device, through K253682 on April 29, 2026. In that summary's reader study of 247 cases, the area under the localization curve rose from 0.626 without AI to 0.724 with it.
Randomized trial
None published
Key study
La Radiologia Medica, 2025, three-reader study of Quantib Prostate with biopsy reference, 110 men
Limits
The published studies are small single-center reader studies of Quantib Prostate with mixed results; the current lesion-detection version has only the company's FDA reader study, and no study tested its effect on biopsy rates or cancer detection in practice.
Cost
No published price found. checked
Specialties
Radiology
Checked against its sources
Grade DLittle or no independent evidence

Rad AI

Generative AI that drafts the impression section of a radiology report from the radiologist's findings.

FDA: not cleared or approved for the use graded
Cost: Rad AI's AWS Marketplace listing, which covers its impression drafting, sets a minimum price of $165,000 a year for up to 150,000 reports on a 36-month contract, with per-report fees at higher volumes.

Full reviewHide full review: Rad AI

Rad AI's software drafts the impression of a radiology report from the findings, clinical indication and imaging protocol, using a model fine-tuned on two to five years of each radiologist's past reports, according to a company-led study, which describes it as a commercially available, domain-specific impression generation system.

Why this grade. The only published study is a retrospective, blinded rating of 200 oncologic CT reports at Moffitt Cancer Center, with Rad AI employees among its authors; it measured how clinicians rated draft impressions, not their effect on care, and with no independent study or FDA review of its data the grade cannot be C.

The evidence

In the Moffitt study, 200 reports from four abdominal radiologists each had three impressions: the original, one drafted by Rad AI's model and one drafted by a general large language model, GPT-4.1. Independent radiologists showed no preference between Rad AI and original impressions (Cohen's h of 0.03, P=0.78); the original authors slightly preferred their own (h=0.18, P=0.07) and rated them more complete (2.87 vs. 2.74 on a 3-point scale). The general model's impressions averaged 75.1 words, against 41.2 for the originals and 34.2 for Rad AI, and were rated much less concise. Raters judged the likelihood of patient harm as low for all three.

Agreement between raters was poor to moderate (Krippendorff's alpha from −0.09 to 0.67). Seven of the 14 authors listed a Rad AI affiliation, including the corresponding author, who also listed Moffitt; no AI impression tool was in clinical use there during the study period.

FDA
No FDA clearance or authorization was found.
Randomized trial
None published
Key study
npj Digital Medicine, 2026, retrospective blinded rating study at Moffitt Cancer Center, 200 oncologic CT reports
Limits
One retrospective study at one academic cancer center, limited to oncologic CT, with 10 raters, low agreement among them and harm judged by opinion rather than observed; it did not measure reporting time, editing or patient outcomes, and company employees led it.
Cost
Rad AI's AWS Marketplace listing, which covers its impression drafting, sets a minimum price of $165,000 a year for up to 150,000 reports on a 36-month contract, with per-report fees at higher volumes. checked
Specialties
Radiology
Checked against its sources
Grade CAccuracy studies only

SubtleMR

Subtle Medical

Vendor-neutral deep learning software that denoises and sharpens MRI images, used to shorten scan protocols.

FDA: 510(k) clearance

Full reviewHide full review: SubtleMR

SubtleMR processes standard MRI images from 1.2T, 1.5T and 3T scanners after acquisition to reduce noise in head, spine, neck and knee MRI or sharpen non-contrast head MRI, its first clearance states. Sites acquire faster, noisier sequences and run them through the software, as in a multicenter spine study that cut scan time by about 40%.

Why this grade. Studies compared image quality and readers' findings on faster, SubtleMR-processed scans with standard scans, led by a prospective multicenter study of 40 brain MRI patients and a 61-patient spine study; none measured an effect on patient care, scanner throughput or outcomes, which a B would require.

The evidence

In a prospective study at five institutions, 40 patients had standard brain MRI and volumetric sequences 60% shorter, processed with SubtleMR; two neuroradiologists rated the processed images better for perceived quality, and volumetric biomarkers and clinical classification did not differ. Authors were from RadNet, Subtle Medical, Cortechs.ai and Stanford. In the spine study at five centers, three neuroradiologists rated 40% faster processed scans better than standard ones for perceived signal-to-noise ratio and artifacts and equivalent for other features; a Subtle Medical employee was an author.

At Mount Sinai, 43 patients with knee pain had conventional (13 minutes 27 seconds) and accelerated processed (6 minutes 45 seconds) knee MRI; two radiologists found no significant differences in diagnosis, image quality or artifacts. One author was from Subtle Medical. A French study with no company authors halved brain acquisition time by halving the image matrix and used SubtleMR to restore resolution in 33 patients with metastases or meningiomas: specificity was 1 and lesion sensitivity 0.92 for radiologists and 0.77 for radiation oncologists; missed lesions were under 4 mm, and image quality was rated lower than on reference scans.

FDA
FDA cleared SubtleMR through 510(k) K191688 on Sept. 16, 2019, as radiological image processing software, and version 2.3 through K223623 on May 11, 2023. The 2019 summary reports tests on retrospective clinical images against acceptance criteria for noise reduction and sharpness, not clinical outcomes.
Randomized trial
None published
Key study
AJNR, 2021, prospective five-institution study of 60% shorter brain MRI sequences, 40 patients
Limits
Most studies were small, rated image appearance on Likert scales and included company employees or partners; none tested whether shorter protocols changed throughput, repeat scans or diagnoses in practice, and the one independent brain study found small lesions missed.
Cost
No published price found. checked
Specialties
Radiology
Checked against its sources

Reviews of the published evidence, not medical advice or an endorsement of any product.